LOS ANGELES — Niagen Bioscience said it has secured a new U.S. patent covering intravenous and injectable formulations and methods of use for nicotinamide riboside, strengthening its intellectual property position in the growing market for NAD+-boosting therapies.
The newly granted U.S. Patent No. 12,558,367 covers methods of using nicotinamide riboside and related derivatives in IV and injectable formats. The company said the patent expands protection for its patented NR ingredient, Niagen®, into delivery formats that are gaining traction in clinical and wellness settings.
“This patent expands our intellectual property for our patented NR ingredient, Niagen®, into IV and injectable delivery formats,” said Rob Fried, CEO of Niagen Bioscience. “With expected protection through 2044, it supports Niagen’s exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding U.S. clinic footprint.”
Niagen Bioscience said it has developed a next-generation intravenous formulation of pharmaceutical-grade Niagen under its Niagen Plus product portfolio. According to the company, the aqueous-based formulation enables faster infusions and raises NAD+ levels more effectively than traditional NAD+ IV treatments, while avoiding the severe side effects often associated with those therapies.
The company said the new patent adds meaningful protection for nicotinamide riboside in IV and injectable delivery formats, with claims covering aqueous formulations, multiple routes of administration, defined dosing parameters, select NR salt forms, and combination use with other NAD+ precursors.
Niagen Bioscience said it owns and licenses a portfolio of more than 100 patents related to Niagen and other NAD+ precursors, supporting its strategy to expand commercially while deterring potential infringers in the rapidly evolving healthy aging market.
